Pfizer (NYSE: PFE) is one of the world's largest drugmakers. That doesn't guarantee the company's success, but it does provide the company with some important long-term advantages.Currently, however,
Pfizer is facing significant headwinds, and the stock has declined roughly 60% from its 2021 highs. For long-term investors who can handle a little adversity, this could be a buying opportunity.A stock doesn't lose 60% of its value randomly, and
Pfizer is dealing with very real issues right now. However, some of that drop is attributable to investor enthusiasm running a bit too hot during the coronavirus pandemic. At that point,
Pfizer was one of the few pharmaceutical companies that was offering a COVID-19 vaccine.Continue reading
Weiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool